Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.56 |
| ▸ | GABRD | O14764 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.56 |
| ▸ | GABRE | P78334 | 2/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7386044 | 0.95 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Nitrous Acid SCHEMBL27923702 | 0.94 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL135492 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29398777 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5709741 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4625244 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9500202 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5002869 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5002408 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4998460 | 0.94 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633334-B1 | TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP | PROCTER & GAMBLE (US) | 2006-11-15 | — | — | EP | claimed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | claimed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | claimed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | claimed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| EP-2931721-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| CN-104662024-A | Tyrosine Kinase Inhibitors | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | disclosed |
| WO-2014090715-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| CN-102417508-A | Fused aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC | 2012-04-18 | — | — | CN | disclosed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6552050-B2 | Adjustment of cellular nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-04-22 | — | — | US | disclosed |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | JACOBSON ELAINE L (US) | 2002-09-05 | — | — | US | disclosed |
| US-6403619-B1 | TOPICALLY ADMINISTERING PRO-NAD COMPOUND (ESTERS OF NICOTINIC ACID) | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| US-6337065-B1 | FOR THERAPY OF DISORDERS SUCH AS SUNBURN AND OTHER SKIN DETERIORATION THAT RESULTS FROM DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-01-08 | — | — | US | disclosed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | disclosed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | GABRP 3410/4885GABRD 3932/4885GABRA1 3961/4885 |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | NAMPT, NADK, NAPRT | GABRP 3389/4885GABRD 4104/4885GABRA1 4310/4885 |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | GABRP 4421/4885GABRD 4578/4885GABRA1 4746/4885 |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | GABRP 3903/4885GABRD 4457/4885GABRA1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.